Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.
Kaplan J, Beenstock D, Belkin M, Crayton H, Eckstein C, Fredericks R, Bian B, Belviso N, Ni D, Rutledge D
J Med Econ. 2026 Dec; 29(1):1701-1713. PMID: 42323726.Abstract
